RT Journal Article
T1 Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy.
A1 Mirelis, Jesús G
A1 Escobar-Lopez, Luis
A1 Ochoa, Juan Pablo
A1 Espinosa, María Ángeles
A1 Villacorta, Eduardo
A1 Navarro, Marina
A1 Casas, Guillem
A1 Mora-Ayestarán, Nerea
A1 Barriales-Villa, Roberto
A1 Mogollón-Jiménez, María Victoria
A1 García-Pinilla, José M
A1 García-Granja, Pablo E
A1 Climent, Vicente
A1 Palomino-Doza, Julian
A1 García-Álvarez, Ana
A1 Álvarez-Barredo, María
A1 Cabrera-Borrego, Eva
A1 Ripoll-Vera, Tomás
A1 Peña-Peña, María Luisa
A1 Rodríguez-González, Elena
A1 Gallego-Delgado, María
A1 Gonzalez-Carrillo, Josefa
A1 Fernández-Ávila, Ana
A1 Rodríguez-Palomares, José F
A1 Brugada, Ramón
A1 Bayes-Genis, Antoni
A1 Dominguez, Fernando
A1 García-Pavía, Pablo
K1 Cardiac magnetic resonance
K1 Dilated cardiomyopathy
K1 End-stage heart failure
K1 Genotype
K1 Late gadolinium enhancement
K1 Sudden cardiac death
AB Genotype and left ventricular scar on cardiac magnetic resonance (CMR) are increasingly recognized as risk markers for adverse outcomes in non-ischaemic dilated cardiomyopathy (DCM). We investigated the combined influence of genotype and late gadolinium enhancement (LGE) in assessing prognosis in a large cohort of patients with DCM. Outcomes of 600 patients with DCM (53.3 ± 14.1 years, 66% male) who underwent clinical CMR and genetic testing were retrospectively analysed. The primary endpoints were end-stage heart failure (ESHF) and malignant ventricular arrhythmias (MVA). During a median follow-up of 2.7 years (interquartile range 1.3-4.9), 24 (4.00%) and 48 (8.00%) patients had ESHF and MVA, respectively. In total, 242 (40.3%) patients had pathogenic/likely pathogenic variants (positive genotype) and 151 (25.2%) had LGE. In survival analysis, positive LGE was associated with MVA and ESHF (both, p  Classification of patients with DCM according to genotype and LGE improves MVA and ESHF prediction. Scar assessment with CMR and genotyping should be considered to select patients for primary prevention implantable cardioverter-defibrillator placement.
YR 2022
FD 2022-05-22
LK http://hdl.handle.net/10668/21940
UL http://hdl.handle.net/10668/21940
LA en
DS RISalud
RD Apr 13, 2025